Athanor Capital, LP 89bio, Inc. Transaction History

Athanor Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$20.22 - $26.73 $353,223 - $466,946	-17,469 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $221,201 - $268,192	9,551 Added 120.62%	17,469 $426,000
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $192,724 - $307,376	7,918 New	7,918 $203,000
Q1 2020 May 14, 2020	SELL	$16.4 - $41.77 $175,414 - $446,771	-10,696 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$19.75 - $33.44 $211,246 - $357,674	10,696 New	10,696 $281,000

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.